A Phase 4 interventional study of rasagiline mesylate and Rasagiline mesylate plus Mirapex in Parkinson's Disease, sponsored by Teva Neuroscience, Inc.. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2011-04-12.
Sponsored by Teva Neuroscience, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing rasagiline in Parkinson Disease — none open to participants now, none under way, none of them phase 3. rasagiline · Parkinson Disease.
Among the 37 studies testing rasagiline in Parkinson Disease, this one is the 14th largest by enrollment, is the only one that started in 2006, is one of 16 in phase 4, and was the 8th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →None of the 37 studies testing rasagiline in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
rasagiline: first FDA approval 2006 (AZILECT), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 17 · Phase 4 16
First in 1997; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 121 across the 37 interventional studies. Of the 31 that completed or were terminated, 13 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 37 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Neuroscience, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Neuroscience, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
19 studies in Parkinson Disease by Teva Pharmaceutical Industries, Ltd.: none open now, none under way, none of them phase 3. Of 19 finished, 3 (16%) have results posted.
Among the 19 studies in Parkinson Disease by Teva Pharmaceutical Industries, Ltd., this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2006, is one of 3 in phase 4, and was the 11th registered.
Teva Pharmaceutical Industries, Ltd.’s Parkinson Disease studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 37 studies testing rasagiline in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Teva Pharmaceutical Industries, Ltd.’s 19 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Requiring therapy for PD symptom control
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rasagiline mesylate
Rasagiline mesylate with one of three adjunct therapies
Drug: Rasagiline mesylate plus Mirapex · Drug: Rasagiline mesylate with Levodopa · Drug: Rasagiline mesylate with Requip
Azilect®
Drug pages: Rasagiline · Pramipexole
Mirapex, Azilect®
Drug pages: Rasagiline · Levodopa
Azilect®, Levodopa
Drug pages: Rasagiline · Ropinirole
Azilect®, Requip
To identify the earliest scheduled visit of symptomatic effect
Time frame: 8 months
To characterize the effectiveness of Azilect in a usual community neurological
Time frame: 8 months
No study locations are listed for this record.
The record gives a start of Oct 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rasagiline · Pramipexole · Levodopa · Ropinirole